OncoMatch

OncoMatch/Clinical Trials/NCT05304962

FIH Study of RGT-419B Alone and With Endocrine Therapy in HR-Positive, HER2-Negative Advanced/Metastatic Breast Cancer

Is NCT05304962 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies multiple treatments including RGT-419B and RGT-419B in combination with hormonal therapy for breast cancer.

Phase 1RecruitingRegor Pharmaceuticals Inc.NCT05304962Data as of May 2026

Treatment: RGT-419B · RGT-419B in combination with hormonal therapyThis is a phase I, First-in-Human (FIH), open-label study to evaluate the safety, tolerability, pharmacokinetic (PK) profile, and preliminary efficacy of RGT-419B administered orally as monotherapy OR in combination with Hormonal Therapy in subjects with HR+, HER2- locally advanced and unresectable (Stage III) or metastatic (Stage IV) breast cancer whose disease has progressed during prior therapy with an approved CDK4/6i plus hormonal therapy.

Check if I qualify

Extracted eligibility criteria

Cancer type

Breast Carcinoma

Biomarker criteria

Required: ESR1 overexpression (ER+)

ER+ ABC consistent with ASCO CAP guidelines

Required: HER2 (ERBB2) wild-type (HER2-)

HER2- ABC consistent with ASCO CAP guidelines

Disease stage

Required: Stage III, IV

Performance status

ECOG 0–1(Restricted strenuous activity)

Prior therapy

Must have received: CDK4/6 inhibitor — metastatic and/or adjuvant

Progression after receiving 1 line of prior cyclin-dependent kinase 4 and 6 inhibitor (CDK4/6i) therapy combined with HT in the MBC setting (up to 1 additional line of CDK4/6i is permitted in the post-surgical adjuvant setting); Subjects must have received therapy for ≥3 months in the MBC setting, or for ≥6 months in the adjuvant setting, prior to progression

Structured fields extracted by AI. May contain errors — verify against the official protocol.

US trial sites

  • University of California, San Diego · La Jolla, California
  • University California, Los Angeles · Los Angeles, California
  • Hem-Onc Associates of the Treasure Coast · Port Saint Lucie, Florida
  • Moffitt Cancer Center · Tampa, Florida
  • Emory University · Atlanta, Georgia

Showing up to 5 US sites. See all sites on ClinicalTrials.gov →

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify